http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010504978-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-5728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-44 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B57-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010504978-A |
| titleOfInvention | Enantiomerically pure phosphoindoles as HIV inhibitors |
| abstract | Provided are 3-phosphoindole compounds in a substantially single enantiomeric form useful for the treatment of flavivirus infections, particularly HLV infections. Also provided are pharmaceutical compositions comprising 3-phosphoindole compounds alone or in combination with one or more antiviral agents, methods for their preparation, and methods for producing pharmaceuticals incorporating these compounds. The 3-phosphoindole compound consists of a compound of formula (A) or (B) and a pharmaceutically acceptable salt, solvate, hydrate or ester thereof. Wherein X is hydrogen; aryl or heterocyclyl; C 2-6 alkenyl, C 2-6 alkynyl or alkyl, Y is hydrogen, —R, —OR, —NH—R or —NRR; Is --OR, --NHR, --NRR, carboxamide, amide, carboxyl, carbonyl or amino acid residue, and R1 is hydrogen, acyl, --S (O) n --R, carboxyl, carbonyl or amino acid residue. Each R 4 ′ , R 5 ′ , R 6 ′ and R 7 ′ is independently hydrogen, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heterocyclyl, halogen, —CN, —CF 3 , -OR, -NHR, a -NRR or -NO 2, n is 0, 1 or 2, each R is independently hydrogen, alkyl, C 2 to 6 alkenyl, C 2 to 6 alkynyl, aryl Or it is heterocyclyl. [Selection] Figure 1B |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11591578-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10704030-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10982197-B2 |
| priorityDate | 2006-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1360.